These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 38115146)

  • 41. The prevalence and prognostic value of BRAF mutation in thyroid cancer.
    Kebebew E; Weng J; Bauer J; Ranvier G; Clark OH; Duh QY; Shibru D; Bastian B; Griffin A
    Ann Surg; 2007 Sep; 246(3):466-70; discussion 470-1. PubMed ID: 17717450
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Assessment of cellularity, genomic DNA yields, and technical platforms for BRAF mutational testing in thyroid fine-needle aspirate samples.
    Dyhdalo K; Macnamara S; Brainard J; Underwood D; Tubbs R; Yang B
    Cancer Cytopathol; 2014 Feb; 122(2):114-22. PubMed ID: 24150898
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical utility of TERT promoter mutations and ALK rearrangement in thyroid cancer patients with a high prevalence of the BRAF V600E mutation.
    Bae JS; Kim Y; Jeon S; Kim SH; Kim TJ; Lee S; Kim MH; Lim DJ; Lee YS; Jung CK
    Diagn Pathol; 2016 Feb; 11():21. PubMed ID: 26857243
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The BRAF(V600E) mutation influences the short- and medium-term outcomes of classic papillary thyroid cancer, but is not an independent predictor of unfavorable outcome.
    Russo M; Malandrino P; Nicolosi ML; Manusia M; Marturano I; Trovato MA; Pellegriti G; Frasca F; Vigneri R
    Thyroid; 2014 Aug; 24(8):1267-74. PubMed ID: 24787545
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A double mutation of BRAF L597Q and V600E in situ and solitary brain metastasis of occult papillary thyroid carcinoma: A case report.
    Chen L; Wu Y; Bai H; Liu H; Li X
    Medicine (Baltimore); 2021 Feb; 100(6):e24458. PubMed ID: 33578538
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical utility of immunohistochemistry for the detection of the BRAF v600e mutation in papillary thyroid carcinoma.
    Zagzag J; Pollack A; Dultz L; Dhar S; Ogilvie JB; Heller KS; Deng FM; Patel KN
    Surgery; 2013 Dec; 154(6):1199-204; discussion 1204-5. PubMed ID: 23931769
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Hobnail variant of papillary thyroid carcinoma].
    Da Cruz V; Lopez J; Lifante JC; Decaussin-Petrucci M
    Ann Pathol; 2021 Apr; 41(2):201-206. PubMed ID: 33272718
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The BRAF V600E mutation in papillary thyroid cancer with positive or suspected pre-surgical cytological finding is not associated with advanced stages or worse prognosis.
    Barbaro D; Incensati RM; Materazzi G; Boni G; Grosso M; Panicucci E; Lapi P; Pasquini C; Miccoli P
    Endocrine; 2014 Apr; 45(3):462-8. PubMed ID: 23925579
    [TBL] [Abstract][Full Text] [Related]  

  • 49. False-negative BRAF V600E mutation results on fine-needle aspiration cytology of papillary thyroid carcinoma.
    Paek SH; Kim BS; Kang KH; Kim HS
    World J Surg Oncol; 2017 Nov; 15(1):202. PubMed ID: 29132392
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A morpho-molecular diagnosis of papillary thyroid carcinoma: BRAF V600E detection as an important tool in preoperative evaluation of fine-needle aspirates.
    Marchetti I; Lessi F; Mazzanti CM; Bertacca G; Elisei R; Coscio GD; Pinchera A; Bevilacqua G
    Thyroid; 2009 Aug; 19(8):837-42. PubMed ID: 19534623
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficient detection of the V600E mutation of the BRAF gene in papillary thyroid carcinoma using multiplex allele-specific polymerase chain reaction combined with denaturing high-performance liquid chromatography.
    Gong RX; Gong YP; Yang J; Wei T; Li-Ling J; Zhu JQ
    Genet Mol Res; 2013 Oct; 12(4):4990-7. PubMed ID: 24301760
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Detection of BRAFV600E mutation on papillary thyroid carcinoma and metastatic malignant melanoma by fine-needle aspiration cytology: how genetic testing may drive toward personalized medicine.
    Rocca BJ; Ambrosio MR; Ginori A; Disanto A
    Diagn Cytopathol; 2014 Oct; 42(10):877-9. PubMed ID: 24574369
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Molecular genotyping of follicular variant of papillary thyroid carcinoma correlates with diagnostic category of fine-needle aspiration cytology: values of RAS mutation testing.
    Lee SR; Jung CK; Kim TE; Bae JS; Jung SL; Choi YJ; Kang CS
    Thyroid; 2013 Nov; 23(11):1416-22. PubMed ID: 23590130
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Diagnostic Value and Challenges of BRAF V600E Molecular Testing and Thyroid Fine-Needle Aspiration Cytology: A Retrospective Study from a Tertiary Institution in Southern Hunan Province, China.
    Lan Z; Yang F; Zhang J; Lan Y; Li H; He R
    Acta Cytol; 2023; 67(6):629-638. PubMed ID: 37708867
    [TBL] [Abstract][Full Text] [Related]  

  • 55. BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma.
    Costa AM; Herrero A; Fresno MF; Heymann J; Alvarez JA; Cameselle-Teijeiro J; García-Rostán G
    Clin Endocrinol (Oxf); 2008 Apr; 68(4):618-34. PubMed ID: 18070147
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The relationship of the BRAF(V600E) mutation and the established prognostic factors in papillary thyroid carcinomas.
    Kurt B; Yalçın S; Alagöz E; Karslıoğlu Y; Yigit N; Günal A; Deveci MS
    Endocr Pathol; 2012 Sep; 23(3):135-40. PubMed ID: 22767446
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical implication of highly sensitive detection of the BRAF V600E mutation in fine-needle aspirations of thyroid nodules: a comparative analysis of three molecular assays in 4585 consecutive cases in a BRAF V600E mutation-prevalent area.
    Lee ST; Kim SW; Ki CS; Jang JH; Shin JH; Oh YL; Kim JW; Chung JH
    J Clin Endocrinol Metab; 2012 Jul; 97(7):2299-306. PubMed ID: 22500044
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Modern aspects influencing the management of patients with papillary thyroid cancer].
    Skibitskaya MV; Kuznetsov NS
    Khirurgiia (Mosk); 2023; (12):89-94. PubMed ID: 38088845
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Reflex BRAF testing in thyroid fine-needle aspiration biopsy with equivocal and positive interpretation: a prospective study.
    Adeniran AJ; Theoharis C; Hui P; Prasad ML; Hammers L; Carling T; Udelsman R; Chhieng DC
    Thyroid; 2011 Jul; 21(7):717-23. PubMed ID: 21568726
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prognostic Significance of TERT Promoter Mutations in Papillary Thyroid Carcinomas in a BRAF(V600E) Mutation-Prevalent Population.
    Lee SE; Hwang TS; Choi YL; Han HS; Kim WS; Jang MH; Kim SK; Yang JH
    Thyroid; 2016 Jul; 26(7):901-10. PubMed ID: 27184112
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.